TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)



Status:Active, not recruiting
Conditions:Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/12/2019
Start Date:March 2014
End Date:September 2019

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of TGR-1202, a Novel PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)

The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in
combination with obinutuzumab (Gazyva) and chlorambucil in patients with chronic lymphocytic
leukemia.


Inclusion Criteria:

- Confirmed Chronic Lymphocytic Leukemia (CLL)

- Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

- Ability to swallow oral medication

Exclusion Criteria:

- Known hepatitis B virus, hepatitis C virus or HIV infection

- Primary central nervous system lymphoma or known intracranial involvement

- Autologous hematologic stem cell transplant within 3 months of study entry or
Allogeneic hematologic stem cell transplant within 12 months
We found this trial at
2
sites
TG Therapeutics Investigational Trial Site
Huntsville, Alabama 35805
?
mi
from
Huntsville, AL
Click here to add this to my saved trials
TG Therapeutics Investigational Trial Site
Memphis, Tennessee 38120
?
mi
from
Memphis, TN
Click here to add this to my saved trials